Profil bibliographique

Eduardo Castañón Álvarez

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

162Publications signalées

354Citations signalées

1Affiliations récentes

Institutions déclarées

Clinica Universidad de Navarra

Domaines associés

Cancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesMelanoma and MAPK PathwaysMonoclonal and Polyclonal Antibodies Research

Publications récentes

Accès ouvert 2026 articleOpenAlex

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study

Benedito A. Carneiro, Thomas U. Marron, Dmitriy Zamarin, Eduardo Castañón Álvarez et autres

0 citationsClinical Cancer Research

Accès ouvert 2026 articleOpenAlex

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study

Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez, Enriqueta Felip et autres

0 citationsClinical Cancer Research

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Methods S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.